Clinical benefit with tebentafusp in a patient with GNAQ mutant metastatic blue nevus-associated melanoma

J Immunother Cancer. 2024 Nov 17;12(11):e009609. doi: 10.1136/jitc-2024-009609.

Abstract

Melanoma arising in association with a blue nevus (BN) is rare but has molecular similarities to uveal melanoma (UM), including GNAQ/11 mutations. Tebentafusp was recently approved for UM based on improved overall survival in a phase 3 study. We hypothesized that tebentafusp may be active in BN-associated melanoma. Here, we present a case of metastatic BN-associated melanoma with rapid response and ~1 year of disease control on tebentafusp. We also explore molecular and histological features of secondary resistance. Our case highlights that PD-1-resistant melanomas should be screened for GNAQ/11 mutations, as tebentafusp may be a treatment option in this extremely rare disease.

Keywords: Bispecific T cell engager - BiTE; Immunotherapy; Melanoma.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • GTP-Binding Protein alpha Subunits / genetics
  • GTP-Binding Protein alpha Subunits, Gq-G11* / genetics
  • Humans
  • Male
  • Melanoma* / drug therapy
  • Melanoma* / genetics
  • Melanoma* / pathology
  • Mutation*
  • Nevus, Blue* / genetics
  • Skin Neoplasms / drug therapy
  • Skin Neoplasms / genetics
  • Skin Neoplasms / pathology
  • Treatment Outcome

Substances

  • GNAQ protein, human
  • GTP-Binding Protein alpha Subunits
  • GTP-Binding Protein alpha Subunits, Gq-G11